IL6 and neoplasm: Tumor samples of siltuximab treated patients showed a decrease in [141] phosphorylated STAT3 and p44/p42 MAPK, which leads to a downregulation of target genes of IL-6 signaling and key enzymes of androgen signaling [142,143].